SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+4.59%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$624M
AUM Growth
+$624M
(+12%)
Cap. Flow
+$64.2M
Cap. Flow
% of AUM
10.29%
Top 10 Holdings %
Top 10 Hldgs %
33.26%
Holding
155
New
31
Increased
26
Reduced
30
Closed
22
Top Buys
| 1 |
Viatris
VTRS
|
$32M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$14.4M |
| 3 |
Amicus Therapeutics
FOLD
|
$9.79M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$9.74M |
| 5 |
Viking Therapeutics
VKTX
|
$7.53M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$18.6M |
| 2 |
Biogen
BIIB
|
$9.81M |
| 3 |
Ituran Location and Control
ITRN
|
$8.27M |
| 4 |
ORBK
Orbotech Ltd
ORBK
|
$6.62M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$5.33M |
Sector Composition
| 1 | Healthcare | 80.48% |
| 2 | Technology | 4.94% |
| 3 | Communication Services | 3.07% |
| 4 | Financials | 1.38% |
| 5 | Consumer Discretionary | 1.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $32.2M | 3.78% | 309,000 +34,000 | +12% | +$3.55M |
|
|
2
Viatris
VTRS
$12.3B
| $32M | 3.76% | +756,449 | New | +$32M |
|
3
Merck
MRK
$210B
| $23.9M | 2.81% | 425,000 | – | – |
|
|
4
Biogen
BIIB
$19.4B
| $23.6M | 2.77% | 74,200 -30,800 | -29% | -$9.81M |
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $21.4M | 2.51% | 384,997 | – | – |
|
6
GSK
GSK
$79.9B
| $16M | 1.87% | 450,000 | – | – |
|
|
7
Amicus Therapeutics
FOLD
$2.34B
| $15.8M | 1.86% | 1,100,000 +680,000 | +162% | +$9.79M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $14.4M | 1.68% | +120,000 | New | +$14.4M |
|
9
Pfizer
PFE
$141B
| $14.1M | 1.66% | 390,000 | – | – |
|
|
CEL
10
DELISTED
Cellcom Israel, Ltd.
CEL
| $14M | 1.65% | 1,359,744 -176,244 | -11% | -$1.82M |
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $13.4M | 1.57% | 86,500 | – | – |
|
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $12.9M | 1.51% | 85,823 +65,000 | +312% | +$9.74M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.7M | 1.26% | 158,000 | – | – |
|
|
PTLA
14
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $10.2M | 1.2% | 210,000 +65,000 | +45% | +$3.16M |
|
15
Nice
NICE
$8.73B
| $9.91M | 1.16% | 107,870 -1,289 | -1% | -$118K |
|
|
CLLS
16
Cellectis
CLLS
$258M
| $9.89M | 1.16% | 339,367 -9,369 | -3% | -$273K |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $9.82M | 1.15% | 60,000 | – | – |
|
|
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
| $9.19M | 1.08% | 344,300 -115,000 | -25% | -$3.07M |
|
|
19
Viking Therapeutics
VKTX
$3.04B
| $8.71M | 1.02% | 2,145,300 +1,855,300 | +640% | +$7.53M |
|
|
TSRO
20
DELISTED
TESARO, Inc.
TSRO
| $7.87M | 0.92% | 95,000 +15,000 | +19% | +$1.24M |
|
21
Prothena Corp
PRTA
$441M
| $7.69M | 0.9% | 205,000 +145,000 | +242% | +$5.44M |
|
|
LJPC
22
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $7.24M | 0.85% | 225,000 +75,000 | +50% | +$2.41M |
|
|
EIGR
23
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $7.14M | 0.84% | 511,469 -8,800 | -2% | -$123K |
|
24
Aldeyra Therapeutics
ALDX
$351M
| $7.1M | 0.83% | 1,044,131 | – | – |
|
25
Visa
V
$683B
| $6.89M | 0.81% | 60,401 +7,450 | +14% | +$849K |
|